Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of OZURDEX 700 μg intravitreal implant in applicator is substantial. |
Clinical Added Value
| minor |
OZURDEX 700 μg intravitreal implant in applicator offers a minor improvement in actual benefit (IAB IV) in the management of the treatment of macular oedema and oedema following either branch retinal vein occlusion or central retinal vein occlusion. |
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
L8Lq8rhNpfshMBn3
